Martin Barraud/OJO Images via Getty Images
Mizuho picks Axsome Therapeutics (AXSM), Wave Life Sciences (WVE), Arcutis Biotherapeutics (ARQT), LivaNova (LIVN), and Humana (HUM) as July’s top picks.
Mizuho put out a list of its top stock picks for the month in every sector.
According to the broker research on Axsome, "While we see >$1bn in peak sales in MDD for Auvelity, we’re also excited about that drug’s potential in Alzheimer’s disease agitation, especially given the unmet medical need, lack of competition, and as a result, the potential revenue opportunity."
When it comes to Humana, Mizuho opines, "We continue to believe the long-term earnings visibility remains high for HUM given the aging of baby boomers, increasing MA penetration in Medicare people, HUM’s leading market position in MA, potential market share gains in Medicaid, and diversity in healthcare services."
Mizuho declares that they are bullish on ARQT as they believe the Zoryve franchise (Foam and Cream) is primed for growth.
XLV is down 0.9% in the last month.